Drug-delivery systems buccal route

Drug Delivery Systems Neutron Scattering Studies / 1049 Drug Delivery Buccal Route / 1071 Drug Delivery Controlled Release / 1082 Drug Delivery Fast-Dissolve Systems / 1104... 

Mucoadhesive drug delivery systems are comprised of administration of drug across the mucosal membrane using a mucoadhesive/bioadhesive polymer through various noninvasive routes such as peroral, ocular, buccal, nasal, stomach, intestinal, colon, vaginal, rectal, cervical or vulval. The drug delivery systems, which have made use of chitosan as a carrier for administration through various routes, have been represented in Table 2.2. 

H. P. Merkle, R. Anders, J. Sandow, and W. Schurr, Drug delivery of peptides The buccal route, in Delivery Systems for Peptide Drugs (S. S. Davis, L. Ilium, and E. Tomlinson, cds.), Plenum Press, New York, 1986, p. 159. 

The buccal mucosa, which lines the inside of the cheek, has been investigated as an alternative route for drug delivery, especially for proteins and peptides. There are many advantages associated with the use of the buccal mucosa as a site for the delivery of drugs into the systemic circulation. Since blood flow from the buccal epithelium drains directly into the internal jugular... 

Shojaei AH (1998) Buccal mucosa as a route for systemic drug delivery A review. J Pham Pharmaceut Sci 1 15-30... 

In comparison to the skin, the buccal mucosa offers higher permeability and faster onset of drug delivery, whereas the key features which help it score over the other mucosal route, the nasal delivery system, include robustness, ease of use, and avoidance of drug metabolism and degradation. The buccal mucosa and the skin have similar structures with multiple cell layers at different degrees of maturation. The buccal mucosa, however, lacks the intercellular lamellar bilayer structure found in the stratum corneum, and hence is more permeable. An additional factor contributing to the enhanced permeability is the rich blood supply in the... 

Due to the lack of activity after oral administration for most peptides and proteins, administration by injection or infusion - that is, by intravenous (IV), subcutaneous (SC), or intramuscular (IM) administration - is frequently the preferred route of delivery for these drug products. In addition, other non-oral administration pathways have been utilized, including nasal, buccal, rectal, vaginal, transder-mal, ocular, or pulmonary drug delivery. Some of these delivery pathways will be discussed in the following sections in the order of the increasing biopharmaceutic challenges to obtain adequate systemic exposure. 

With the advent of new biotechnological techniques endogenous compounds like insulin, buserelin or octreotide have become available at affordable prices. All of these substances still have to undergo needle application. Until today the development of alternative delivery systems for the nasal, buccal, peroral, rectal and pulmonary routes for the administration of those class III drugs according to the biopharmaceutics classification system (BCS) (Amidon et al. 1995) could not keep pace with this development of endogenous compounds or is not economic enough for the health care payers (e.g. insulin application via the pulmonary route). 

The term mucoadhesion is commonly used to describe an interaction between the mucin layer, which lines the entire GI tract, and a bioadhesive polymer, which could be natural or synthetic in origin.From the oral delivery standpoint, these systems are used to immobilize and localize a drug delivery device in the selected regions of the GI tract, which could be an oral cavity (buccal and sublingual routes), the esophagus, stomach, small intestine, or colon (oral route). For the most part, research in this area has focused on the design of polymeric micro- and nanoparticulate systems that use hydrophilic polymers, primarily due to their propensity to interact with the mucosal surface. ... 

Shojaei AH, Chang RK, Guo X, et al. Systemic drug delivery via the buccal mucosal route. Pharm Technol 2001 25(6) 70—81. 

The lack of activity after oral administration for most peptides and proteins resulted in the past besides parenteral application into the utilization of nonoral administration pathways, for example, nasal, buccal, rectal, vaginal, percutaneous, ocular, or pulmonary drug delivery [27]. Drug delivery via these administration routes, however, is also frequently accompanied by presystemic degradation processes. Bioavailability of numerous peptides and proteins is, for example, markedly reduced after subcutaneous or intramuscular administration compared to their intravenous administration. The pharma-cokinetically derived apparent absorption rate constant is thus the combination of absorption into the systemic circulation and presystemic degradation at the absorption... 

---